160 related articles for article (PubMed ID: 27802782)
41. Correspondence re: T. Davis et al., therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5: 611-615, 1999.
Grillo-López AJ; Kunkel L
Clin Cancer Res; 2000 Jan; 6(1):317-8. PubMed ID: 10656464
[No Abstract] [Full Text] [Related]
42. CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes.
Vauchy C; Gamonet C; Ferrand C; Daguindau E; Galaine J; Beziaud L; Chauchet A; Henry Dunand CJ; Deschamps M; Rohrlich PS; Borg C; Adotevi O; Godet Y
Int J Cancer; 2015 Jul; 137(1):116-26. PubMed ID: 25449106
[TBL] [Abstract][Full Text] [Related]
43. Anti-HER-2 anti-CD3 bi-specific antibodies inhibit growth of HCT-116 colorectal carcinoma cells in vitro and in vivo.
Ren H; Li J; Liu JJ; Guo HL; Jiang T
Asian Pac J Cancer Prev; 2012; 13(6):2795-8. PubMed ID: 22938461
[TBL] [Abstract][Full Text] [Related]
44. Anti-CD20 monoclonal antibodies: historical and future perspectives.
Lim SH; Beers SA; French RR; Johnson PW; Glennie MJ; Cragg MS
Haematologica; 2010 Jan; 95(1):135-43. PubMed ID: 19773256
[TBL] [Abstract][Full Text] [Related]
45. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
Davis TA; Czerwinski DK; Levy R
Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
[TBL] [Abstract][Full Text] [Related]
46. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells.
Piccione EC; Juarez S; Liu J; Tseng S; Ryan CE; Narayanan C; Wang L; Weiskopf K; Majeti R
MAbs; 2015; 7(5):946-56. PubMed ID: 26083076
[TBL] [Abstract][Full Text] [Related]
47. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
[TBL] [Abstract][Full Text] [Related]
48. Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies.
De Gast GC; Van Houten AA; Haagen IA; Klein S; De Weger RA; Van Dijk A; Phillips J; Clark M; Bast BJ
J Hematother; 1995 Oct; 4(5):433-7. PubMed ID: 8581381
[TBL] [Abstract][Full Text] [Related]
49. Immunotherapy with bispecific antibodies.
Thielemans KM
Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
[TBL] [Abstract][Full Text] [Related]
50. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N
J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972
[TBL] [Abstract][Full Text] [Related]
51. Development of a mimotope-based vaccine against CD20 antigen.
Li M; Han W; Zhang Q; Xue X; Wang Z; Zhang Y
Protein Pept Lett; 2007; 14(6):610-4. PubMed ID: 17627604
[TBL] [Abstract][Full Text] [Related]
52. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
Robak T
Curr Opin Investig Drugs; 2009 Jun; 10(6):588-96. PubMed ID: 19513948
[TBL] [Abstract][Full Text] [Related]
53. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody.
Bleeker WK; Munk ME; Mackus WJ; van den Brakel JH; Pluyter M; Glennie MJ; van de Winkel JG; Parren PW
Br J Haematol; 2008 Feb; 140(3):303-12. PubMed ID: 18045353
[TBL] [Abstract][Full Text] [Related]
54. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
55. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
[TBL] [Abstract][Full Text] [Related]
56. Genome-scale CRISPR activation screen uncovers tumor-intrinsic modulators of CD3 bispecific antibody efficacy.
Decker CE; Young T; Pasnikowski E; Chiu J; Song H; Wei Y; Thurston G; Daly C
Sci Rep; 2019 Dec; 9(1):20068. PubMed ID: 31882897
[TBL] [Abstract][Full Text] [Related]
57. The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies.
Ahmadzadeh V; Tofigh R; Farajnia S; Pouladi N
Int Rev Immunol; 2016; 35(2):136-55. PubMed ID: 26325124
[TBL] [Abstract][Full Text] [Related]
58. Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice.
Chu Y; Hochberg J; Yahr A; Ayello J; van de Ven C; Barth M; Czuczman M; Cairo MS
Cancer Immunol Res; 2015 Apr; 3(4):333-44. PubMed ID: 25492700
[TBL] [Abstract][Full Text] [Related]
59. The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma.
Lykken JM; Tedder TF
Cancer J; 2015; 21(4):351-6. PubMed ID: 26222089
[TBL] [Abstract][Full Text] [Related]
60. BL-01, an Fc-bearing, tetravalent CD20 × CD5 bispecific antibody, redirects multiple immune cells to kill tumors in vitro and in vivo.
Interdonato A; Choblet S; Sana M; Valgardsdottir R; Cribioli S; Alzani R; Roth M; Duonor-Cerutti M; Golay J
Cytotherapy; 2022 Feb; 24(2):161-171. PubMed ID: 34538717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]